Merck Sharp & Dohme Corp. - Recruiting 18 years or older. - A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy.
Bristol-Myers Squibb - Recruiting 18 years or older. - A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy.
City of Hope Medical Center - Recruiting 65 years or older. - Delivering the Geriatric Assessment Tool to Older Adults With Cancer Using Computer Survey Methodologies: Testing Feasibility, Reliability, and Validity of Research Electronic Data Capture (REDCap) and Support Screen (Touchscreen) Technologies.
Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years. - Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV.
Nantes University Hospital - Recruiting 12 Months to 18 years. - Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens.
Fludarabine IV- Busulfan IV (Busilvexr) - Anti-thymocyte globulines (Thymoglobuliner)
Asan Medical Center - Recruiting 15 years or older. - The Correlation of Voriconazole Trough Plasma Levels With Genetic Polymorphism, Efficacy, and Safety Outcomes in Hematologic Malignancy Patients With Invasive Pulmonary Aspergillosis.
Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older. - A Phase II Study to Assess the Efficacy of Maraviroc, a CCR5-Antagonist in Prophylaxis of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic Stem-Cell Transplantation From Unrelated Donors.
Thomas Jefferson University - Recruiting 18 years or older. - A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies From One Versus Two HLA Partially-Matched Related Donors.
Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide; Stem Cell Infusion